Stock UCBJY UCB SA
Add to a list
To use this feature you must be a member
Log inSign up

Financials UCB SA OTC Markets

Equities

UCBJY

US9034801012

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 03:52:12 2024-07-16 pm EDT 		5-day change 1st Jan Change
77.77 USD -0.71% Intraday chart for UCB SA -0.04% +78.37%
Jun. 20 Kepler Cheuvreux Downgrades UCB to Hold from Buy, Raises PT MT
Jun. 13 UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 13,355 15,962 18,947 13,973 14,969 27,068 - -
Enterprise Value (EV) 1 13,343 17,373 19,807 15,973 17,146 28,738 27,901 26,903
P/E ratio 16.8 x 21.8 x 17.9 x 33.4 x 44.8 x 68.1 x 32.2 x 23.2 x
Yield 1.75% 1.5% 1.3% 1.81% 1.72% 0.99% 1.01% 1.02%
Capitalization / Revenue 2.72 x 2.99 x 3.28 x 2.53 x 2.85 x 4.79 x 4.21 x 3.77 x
EV / Revenue 2.72 x 3.25 x 3.43 x 2.9 x 3.26 x 5.09 x 4.33 x 3.75 x
EV / EBITDA 9.32 x 12.1 x 12.1 x 12.7 x 12.7 x 21.1 x 14.4 x 11.3 x
EV / FCF 17 x 21.1 x 15.6 x 18.4 x 38.5 x 29 x 20 x 15.2 x
FCF Yield 5.87% 4.75% 6.42% 5.43% 2.6% 3.45% 5% 6.6%
Price to Book 1.9 x 2.2 x 2.32 x 1.58 x 1.67 x 2.95 x 2.75 x 2.47 x
Nbr of stocks (in thousands) 188,367 188,941 188,812 189,959 189,721 189,751 - -
Reference price 2 70.90 84.48 100.4 73.56 78.90 142.6 142.6 142.6
Announcement Date 2/20/20 2/25/21 2/24/22 2/22/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 4,913 5,347 5,777 5,517 5,252 5,651 6,437 7,181
EBITDA 1 1,431 1,441 1,641 1,260 1,349 1,363 1,939 2,378
EBIT 1 1,118 1,093 1,318 675 657 696.4 1,246 1,662
Operating Margin 22.76% 20.44% 22.81% 12.23% 12.51% 12.32% 19.36% 23.15%
Earnings before Tax (EBT) 1 960 880 1,226 511 441 500.5 1,085 1,566
Net income 1 792 732 1,058 418 343 405.7 860.6 1,261
Net margin 16.12% 13.69% 18.31% 7.58% 6.53% 7.18% 13.37% 17.56%
EPS 2 4.230 3.870 5.600 2.200 1.760 2.094 4.428 6.153
Free Cash Flow 1 783 825 1,271 867 445 992 1,395 1,775
FCF margin 15.94% 15.43% 22% 15.72% 8.47% 17.55% 21.68% 24.71%
FCF Conversion (EBITDA) 54.72% 57.25% 77.45% 68.81% 32.99% 72.78% 71.95% 74.63%
FCF Conversion (Net income) 98.86% 112.7% 120.13% 207.42% 129.74% 244.51% 162.13% 140.71%
Dividend per Share 2 1.240 1.270 1.300 1.330 1.360 1.408 1.444 1.449
Announcement Date 2/20/20 2/25/21 2/24/22 2/22/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 Q2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 2,590 2,608 2,739 2,778 2,999 - 2,925 2,592 2,589 2,663 2,687 2,940
EBITDA 707 783 658 843 798 - 814 446 801 548 584.5 -
EBIT 1 547 614 479 682 636 234 551 124 486 171 274.1 437.4
Operating Margin 21.12% 23.54% 17.49% 24.55% 21.21% - 18.84% 4.78% 18.77% 6.42% 10.2% 14.88%
Earnings before Tax (EBT) 416 458 422 643 583 - 481 30 401 40 - -
Net income 381 363 369 571 487 - 399 19 311 32 - -
Net margin 14.71% 13.92% 13.47% 20.55% 16.24% - 13.64% 0.73% 12.01% 1.2% - -
EPS 2.030 1.920 1.950 3.020 2.580 - 2.100 0.1000 1.600 - - -
Dividend per Share - - - - - - - - - - - -
Announcement Date 2/20/20 7/27/20 2/25/21 7/29/21 2/24/22 7/28/22 7/28/22 2/22/23 7/27/23 2/28/24 - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 1,411 860 2,000 2,177 1,670 833 -
Net Cash position 1 12 - - - - - - 165
Leverage (Debt/EBITDA) - 0.9792 x 0.5241 x 1.587 x 1.614 x 1.225 x 0.4297 x -
Free Cash Flow 1 783 825 1,271 867 445 992 1,395 1,775
ROE (net income / shareholders' equity) 14.6% 14.2% 15.7% 9.5% 8.83% 7.71% 12.2% 14%
ROA (Net income/ Total Assets) 7.34% 8.32% 8.91% 5.51% 5.07% 3.48% 5.25% 6.37%
Assets 1 10,798 8,798 11,878 7,583 6,767 11,646 16,402 19,792
Book Value Per Share 2 37.30 38.50 43.20 46.60 47.30 48.30 51.90 57.90
Cash Flow per Share 2 4.710 5.570 8.000 5.740 3.900 5.420 7.750 9.690
Capex 1 99 256 282 252 316 265 288 317
Capex / Sales 2.02% 4.79% 4.88% 4.57% 6.02% 4.69% 4.47% 4.42%
Announcement Date 2/20/20 2/25/21 2/24/22 2/22/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for UCB SA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
142.6 EUR
Average target price
140.3 EUR
Spread / Average Target
-1.66%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
+7.40% 101B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+8.42% 42.18B
BIOGEN INC. Stock Biogen Inc.
-13.04% 32.26B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-10.92% 16.06B
INCYTE CORPORATION Stock Incyte Corporation
+1.93% 14.45B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-6.77% 12.01B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+177.16% 10.71B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.12% 8.89B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-56.13% 8.83B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. UCB Stock
  4. UCBJY Stock
  5. Financials UCB SA